Detalhe da pesquisa
1.
Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.
Cancer
; 130(11): 1991-2002, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38404184
2.
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia.
Eur J Clin Pharmacol
; 80(1): 105-113, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37917187
3.
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer.
Br J Cancer
; 129(10): 1608-1618, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37731023
4.
Oncology phase II proof-of-concept studies with multiple targets: Randomized controlled trial or single arm?
Pharm Stat
; 19(2): 117-125, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31424631
5.
Tumor growth inhibition-overall survival modeling in non-small cell lung cancer: A case study from GEMSTONE-302.
CPT Pharmacometrics Syst Pharmacol
; 13(3): 437-448, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38111189
6.
Can a propensity score matching method be applied to assessing efficacy from single-arm proof-of-concept trials in oncology?
CPT Pharmacometrics Syst Pharmacol
; 12(9): 1347-1357, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37528543
7.
STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
Mol Cancer Ther
; 21(2): 282-293, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34815361
8.
90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
Mol Pharmacol
; 75(1): 124-33, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18820127
9.
A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.
Pancreatology
; 9(4): 404-9, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19451750
10.
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
Clin Cancer Res
; 14(20): 6704-11, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18927314
11.
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Mol Cancer Ther
; 7(9): 2955-66, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18790776
12.
Targeting checkpoint kinase 1 in cancer therapeutics.
Clin Cancer Res
; 13(7): 1955-60, 2007 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17404075
13.
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Clin Cancer Res
; 13(2 Pt 1): 591-602, 2007 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17255282
14.
A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development.
Contemp Clin Trials
; 64: 238-242, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28966137
15.
Characterization of murine CEACAM1 in vivo reveals low expression on CD8+ T cells and no tumor growth modulating activity by anti-CEACAM1 mAb CC1.
Oncotarget
; 9(77): 34459-34470, 2018 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30349641
16.
Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
Cancer Res
; 78(10): 2721-2731, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29490944
17.
Aurora kinases: new targets for cancer therapy.
Clin Cancer Res
; 12(23): 6869-75, 2006 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17145803
18.
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
J Clin Oncol
; 23(9): 1803-10, 2005 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-15677699
19.
Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Cancer Res
; 64(18): 6635-44, 2004 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15374978
20.
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST.
J Clin Oncol
; 38(23): 2667-2676, 2020 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32552274